Rhovica

Rhovica operates in a specialized segment of medical devices focused on emergency neurosurgical access and visualization. Its SoNav platform targets external ventricular drain placement, a procedure used to drain cerebrospinal fluid and monitor intracranial pressure in patients with conditions such as severe trauma or brain bleeding. The company’s differentiation is centered on real-time guidance and monitoring during urgent procedures, addressing situations in which clinicians may otherwise rely heavily on pre-acquired CT imaging and indirect anatomical positioning. The product is therefore closer to procedure-specific surgical guidance than to general diagnostic imaging or broad digital-health software. Rhovica’s competitive context includes established neuro-navigation, ultrasound-guidance, and intracranial-pressure monitoring providers, but no specific competitor set is identified in the available company information. Its CHF 2.3 million 2025 seed round, SoNav-focused innovation voucher, and 2026 medtech selection suggest early commercial and clinical development rather than mature market penetration. The main strategic challenge is converting a technically differentiated workflow into validated clinical evidence, regulatory clearance, and routine adoption across emergency and neurosurgical settings.

Rhovica’s growth trajectory shows a progression from grant-backed formation to a larger seed-financed product-development phase. The company was founded in 2021 and received three early grants: $10,832 on Mar 30, 2022, $20,111 on Jun 15, 2022, and $161,869 on Dec 21, 2022, all associated with Venture Kick. These awards appear to have supported initial technology development and feasibility work. The inflection point came on Aug 26, 2025, when Rhovica announced a CHF 2.3 million seed round led by M2care, with Kickfund and Valuemaker also participating. The company has described team expansion to support prototyping and pre-clinical studies, although its disclosed employee band remains one to ten people. Product development is concentrated on SoNav, an EVD catheter system designed for rapid placement, visualization, and monitoring. The 2025 sitem-insel Innovation Voucher selection and the 2026 Ypsomed Innovation Award finalist status provide additional signals of validation. Appointment of Carsten Laue to the board on Aug 25, 2025 further strengthened strategic and clinical-commercial guidance. The next trajectory-defining milestones are likely regulatory progress, pre-clinical evidence, clinical adoption, and conversion of early partnerships and recognition into hospital use.